Broader economic impact on vaccines (BEIV)
28-29 June 2012, Geneva, Switzerland
IVR embarked on a new work programme on the broader economic impact on vaccines in 2011. As part of this work program, IVR issued a request for proposals on BEIV with the aim to encourage development of innovative tools to measure, value and obtain country evidence on broader economic impact on vaccines. In total four proposals were awarded beginning of 2012.
The Fiscal Consequences of Vaccination for Government: A Government Perspective Assessment of Tax Revenue and Transfers Associated to Changes in Population Health Status Attributed to Immunization
To develop an easy-to-use tool for assessment of macroeconomic impact of vaccine preventable disease targeted at generalist policymakers and country-level ministries of health
To develop a novel tool to assess the broader economic and health benefits of delivering a combination of interventions integrated onto the same vaccination platform: case study of current Indian supplemental immunization activities (SIAs) to deliver a second dose of measles-containing vaccine (MCV2).
To explore the broader economic benefits of prospective group A strep vaccination (GAS) - Phase I: a cost-of-illness study of rheumatic heart disease and invasive group A strep.
The objectives of the consultation were to:
- present and discuss the interim results of the four awarded study proposals.
- propose modifications to the study proposals if possible based on feedback and comments from the meeting participants.
The meeting had the following expected outcomes:
- A common understanding of the different study proposals by the participants; and
- Agreed study proposals which contribute to the overall WHO framework on the broader economic impact on vaccines.